- Cabrera Serrano, Antonio José|||0000-0003-0346-7960
- Sánchez Maldonado, José Manuel|||0000-0002-4651-3675
- ter Horst, Rob|||0000-0003-0576-5873
- Macauda, Angelica|||0000-0001-9820-5079
- García Martín, Paloma|||0000-0001-5582-8575
- Benavente, Yolanda|||0000-0003-1422-4614
- Landi, Stefano|||0000-0001-8364-6357
- Clay-Gilmour, Alyssa|||0000-0001-9998-4879
- Niazi, Yasmeen|||0000-0002-7560-2247
- Espinet Solà, Blanca|||0000-0002-4294-8145
- Rodriguez-Sevilla, Juan Jose|||0000-0002-4741-7925
- Pérez, Eva María
- Maffei, Rossana|||0000-0002-3518-2006
- Blanco, Gonzalo|||0000-0001-6557-3764
- Giaccherini, Matteo|||0000-0002-0363-6632
- Cerhan, James R.
- Marasca, Roberto|||0000-0002-6431-6878
- Lopez Nevot, Miguel Angel|||0000-0002-3465-6062
- Chen-Liang, Tzu Hua
- Thomsen, Hauke|||0000-0001-5951-3116
- Gámez, Irene
- Campa, Daniele|||0000-0003-3220-9944
- Moreno Aguado, Victor Raul|||0000-0002-2818-5487
- de Sanjosé, Silvia
- Marcos-Gragera, Rafael|||0000-0001-9824-3657
- García-Álvarez, María Flor
- Dierssen-Sotos, Trinidad|||0000-0002-6127-0077
- Jerez, Andrés|||0000-0002-2079-6638
- Butrym, Aleksandra|||0000-0002-8199-2018
- Norman, Aaron D.|||0000-0002-4208-2708
- Luppi, Mario|||0000-0002-0373-1154
- Slager, Susan|||0000-0002-5173-4712
- Hemminki, Kari|||0000-0002-2769-3316
- Li, Yang
- Berndt, Sonja
- Casabonne, Delphine
- Alcoceba, Miguel|||0000-0002-3819-4846
- Puiggros, Anna|||0000-0001-9627-4978
- Netea, Mihai G.|||0000-0003-2421-6052
- Försti, Asta|||0000-0002-9857-4728
- Canzian, Federico|||0000-0002-4261-4583
- Sainz, Juan|||0000-0002-9355-2423
Chronic lymphocytic leukemia (CLL) is the most common leukemia among adults worldwide. Although genome-wide association studies (GWAS) have uncovered the germline genetic component underlying CLL susceptibility, the potential use of GWAS-identified risk variants to predict disease progression and patient survival remains unexplored. Here, we evaluated whether 41 GWAS-identified risk variants for CLL could influence overall survival (OS) and disease progression, defined as time to first treatment (TTFT) in a cohort of 1039 CLL cases ascertained through the CRuCIAL consortium. Although this is the largest study assessing the effect of GWAS-identified susceptibility variants for CLL on OS, we only found a weak association of ten single nucleotide polymorphisms (SNPs) with OS (p < 0.05) that did not remain significant after correction for multiple testing. In line with these results, polygenic risk scores (PRSs) built with these SNPs in the CRuCIAL cohort showed a modest association with OS and a low capacity to predict patient survival, with an area under the receiver operating characteristic curve (AUROC) of 0.57. Similarly, seven SNPs were associated with TTFT (p < 0.05); however, these did not reach the multiple testing significance threshold, and the meta-analysis with previous published data did not confirm any of the associations. As expected, PRSs built with these SNPs showed reduced accuracy in prediction of disease progression (AUROC = 0.62). These results suggest that susceptibility variants for CLL do not impact overall survival and disease progression in CLL patients.